Drug Device Combination
Products

The National Medical Products Administration (NMPA) defines drug-device combination products as medical products composed of both drugs and medical devices, integrated into a single entity.

To register a combination product with the NMPA, you must first determine the product’s Primary Mode of Action (PMOA):

Drug-led combination products registration applications must be submitted to the Center for Drug Evaluation (CDE)
Device-led combination products must be submitted to the Center for Medical Device Evaluation (CMDE).

If the device PMOA is unclear, applicants can apply for an attribute definition from the NMPA’s Center for Medical Device Standards Management (CMDSM) before submitting the premarket approval application.

Single entity combination products
Drug products inside delivery device

Joint Evaluation of Drug Device 
Combination Products

During a joint evaluation, the CDE and CMDE collaborate to assess the product's safety, effectiveness, and quality control. Each center issues an evaluation report covering its respective component, and the leading unit consolidates these findings into an overall evaluation report. This report is then submitted to the relevant NMPA department for administrative approval.

For drug-led combination products, the CDE leads the evaluation. If a joint evaluation is required, the application dossier is transferred to the CMDE for synchronized evaluation.

For device-led combination products, the CMDE leads the evaluation. If a joint evaluation is required, the dossier is transferred to the CDE.

During a joint evaluation, the CDE and CMDE collaborate to assess the product's safety, effectiveness, and quality control. Each center issues an evaluation report covering its respective component, and the leading unit consolidates these findings into an overall evaluation report. This report is then submitted to the relevant NMPA department for administrative approval.

Our China Drug-Device Combination Product Services

With expertise in both pharmaceutical and medical device regulations, we assist with the classification, registration and compliance of both drug and device-led combination products.

Our services include:

Regulatory Pathway Assessment

If uncertain, we assist in applying for an attribute definition with the Center for Medical Device Standards Management (CMDSM).
Determine the product’s primary mode of action (PMOA) to classify it as drug-led or device-led.

Registration Strategy Development

Develop a customized regulatory strategy aligned with the requirements of the Center for Drug Evaluation (CDE) or the Center for Medical Device Evaluation (CMDE), depending on the product’s classification.
Coordinate with both centers for joint evaluations as required.

Dossier Preparation & Submission

Ensure that documentation covers both drug and device components, including safety, efficacy, and quality control data including the necessary type testing in China.
Prepare and compile the registration dossier, ensuring compliance with NMPA guidelines.
Submit the application through the NMPA online platform.

Clinical Trial Application (CTA)

Ensure compliance with Good Clinical Practice (GCP) standards for both drug and device components.
Assist in obtaining approval for clinical trials if required.

Communication & Coordination with Regulatory Authorities

Liaise with the CDE and CMDE to facilitate the evaluation process.
Address enquiries and provide additional documentation as requested by regulators.

Post-Approval Compliance

Ensure compliance with post-market surveillance requirements, including pharmacovigilance and medical device vigilance.
Support registration renewals, variations, and amendments.

Request a Proposal from Our Life Sciences Team about Your Combination Product

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

Digital Medical Device Clinical Trials in South Korea: Understanding the MFDS Framework

Understand MFDS clinical trial requirements for digital medical devices, including real-world evidence, data-based studies, and software validation expectations.

June 2, 2026
Digital Medical Device Clinical Trials in South Korea: Understanding the MFDS Framework

Cisema Expands into South Korea

Supporting foreign manufacturers entering South Korea with regulatory services for medical devices, IVDs, and quasi-drugs.

June 1, 2026
Cisema Expands into South Korea
Seoul skyline in the early evening

Indonesia Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Learn which products are covered by Indonesia's halal framework, the labeling and manufacturing obligations, and phased compliance timelines.

May 20, 2026
Indonesia Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know
A healthcare worker in a white coat checks a seated patient’s blood pressure while another medical staff member in green scrubs stands nearby holding a clipboard in a bright clinic setting.

Medical Device Market Access for Thailand, Indonesia, and the Philippines

Cisema offers regulatory insight and market access strategy for medical devices in Thailand, Indonesia, and the Philippines.

May 15, 2026
Medical Device Market Access for Thailand, Indonesia, and the Philippines
Medical Device Market Access for Thailand, Indonesia, and the Philippines

Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Learn how to register medical devices in Indonesia, including Authorized Representative rules, classification, dossiers, timelines, and fees.

May 15, 2026
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers
Three masked surgical staff in green operating room attire stand with folded arms beside a patient lying on an operating table, with medical monitors and X-ray images displayed in a dimly lit operating room.”

Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers

Understand the pathway for intraocular lens (IOL) registration in China, including NMPA requirements and key compliance steps.

May 14, 2026
Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers
A close-up of an eye with a transparent intraocular lens held by surgical tweezers positioned in front of the pupil, illustrating ophthalmic medical device use. The visual supports themes of regulatory compliance, product registration, and market access
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

Pharmaceutical Development & Strategy Consulting

We assess your product’s market viability and identify development gaps to enhance readiness. We create tailored regulatory and clinical strategies aligned with Chinese health authority requirements, ensuring clear and compliant communication for streamlined approval.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Latest Insights

View More

MFDS Issues 2025 Korea Medical Device Regulatory Update Report

Summary of 2025 MFDS trends covering medical device approvals, import dynamics, and the shift toward AI and software-based regulation.

June 2, 2026
MFDS Issues 2025 Korea Medical Device Regulatory Update Report

China Revises Recombinant Insulin Technical Guideline for Drug Development and Quality Control

The updated technical guideline expands regulatory expectations for manufacturing, impurity control, advanced analytics, stability studies, and biosimilar comparability.

June 2, 2026
China Revises Recombinant Insulin Technical Guideline for Drug Development and Quality Control
A Chinese adult with diabetes seated at a kitchen table in a bright contemporary apartment, carefully preparing an insulin injection using an insulin pen beside a blood glucose meter and prescription supplies.

China Issues Revised Measures Governing Pharmaceutical Representatives and Academic Promotion Activities

China’s NMPA and six government agencies issued new measures that strengthen compliance requirements, anti-bribery controls, and oversight of pharmaceutical promotion activities.

June 1, 2026
China Issues Revised Measures Governing Pharmaceutical Representatives and Academic Promotion Activities
Pharmaceutical industry professional walking through a bright modern pharmaceutical facility, wearing business-casual attire and carrying a tablet, surrounded by pharmaceutical workspaces with clean laboratory benches and sealed medicine.

China Issues Landmark Regulation on Biomedical New Technologies

The new framework introduces a distinct regulatory pathway for emerging therapies, with major implications for clinical development and market strategy.

June 1, 2026
China Issues Landmark Regulation on Biomedical New Technologies

China Proposes Sweeping New Rules for Drugs, Medical Devices, and Special Foods Advertising

China’s SAMR has released draft advertising review measures that would increase oversight of livestreaming and digital marketing while streamlining certain compliance requirements for regulated products.

June 1, 2026
China Proposes Sweeping New Rules for Drugs, Medical Devices, and Special Foods Advertising

China CDE Issues Clinical Evaluation Guidelines for Drug Clinical Trial & Marketing Authorization Applications

New guidance highlights the need for earlier China development planning whenrelying on global trials, foreign clinical data, or multinational development strategies

May 29, 2026
China CDE Issues Clinical Evaluation Guidelines for Drug Clinical Trial & Marketing Authorization Applications
Pharmaceutical scientist in a modern drug development laboratory in China, standing beside a clean laboratory bench while examining a small sample vial and discussing research with a colleague
Previous
Previous

Get in Touch with Our Life Sciences Team

And discover how we can support you in achieving approval for your drug-device combination product in China.

Request Proposal